πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 134 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10851158

Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10787490

Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Protagonist Therapeutics, Inc. Β· Granted Tue Sep 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10781242

Interleukin-2 fusion proteins and uses thereof

Medicenna Therapeutics Inc. Β· Granted Tue Sep 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10774141

Antibody for binding to interleukin 4 receptor

SuZhou Connect Biopharmaceuticals, Inc. Β· Granted Tue Sep 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10738112

Anti-human interleukin-17A monoclonal antibody

SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. Β· Granted Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10696724

Activatable interleukin-2 polypeptides

Werewolf Therapeutics, Inc. Β· Granted Tue Jun 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10696723

Activatable interleukin 12 polypeptides

Werewolf Therapeutics, Inc. Β· Granted Tue Jun 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10611845

Activatable antibodies that bind interleukin-6 receptor and methods of use thereof

CytomX Therapeutics, Inc. Β· Granted Tue Apr 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10435473

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10196424

Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bow

Protagonist Therapeutics, Inc. Β· Granted Tue Feb 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10166288

Vaccines having an antigen and interleukin-21 as an adjuvant

Inovio Pharmaceuticals, Inc. Β· Granted Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10130705

Vaccines with interleukin-33 as an adjuvant

Inovio Pharmaceuticals, Inc. Β· Granted Tue Nov 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10106592

Interleukin-4 receptor-binding fusion proteins and uses thereof

Medicenna Therapeutics Inc. Β· Granted Tue Oct 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10093708

Interleukin-4 receptor-binding fusion proteins and uses thereof

Medicenna Therapeutics Inc. Β· Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10072086

Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10035824

Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bow

Protagonist Therapeutics, Inc. Β· Granted Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10023614

Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bow

Protagonist Therapeutics, Inc. Β· Granted Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10005834

Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 26 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9840558

Human antibody specific for interleukin-1alpha

XBIOTECH INC. Β· Granted Tue Dec 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9669091

Vaccines having an antigen and interleukin-23 as an adjuvant

Inovio Pharmaceuticals, Inc. Β· Granted Tue Jun 06 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 01 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9624268

Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bow

Protagonist Therapeutics, Inc. Β· Granted Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9487590

Activatable antibodies that bind interleukin-6 receptor and methods of use thereof

CytomX Therapeutics, Inc. Β· Granted Tue Nov 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9475839

Peptide-based inhibitor of interleukin-10 or interferon-gamma signaling

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Oct 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9339528

Methods for treating epithelium trauma of the intestinal mucosa using interleukin-1 recept

GENERAL REGENERATIVES, LTD. Β· Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted